Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
30 mai 2023 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB-100 May Be a General Method for Enhancing the Effectiveness of Immunotherapy in Refractory Cancers PASADENA, CA, May 30, 2023 ...